The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback